Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Allen Dennis

Interventional Pain Medicine Georgetown, TX Medical Doctor

NPI 1912044793 CMS profile 177731

3316 Williams Dr Ste 150, Ste 201, Georgetown, TX 78628

Open in the dashboard

General payments

$51,639

1,260 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$13,535 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Allen Dennis of Georgetown, TX is reported in the CMS Open Payments database as having received $51,639 across 1,260 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $13,535 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,564 21
2024 General $11,515 73
2023 General $4,182 81
2022 General $14,851 252
2021 General $5,950 423
2020 General $2,831 237
2019 General $2,745 173

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Allen Dennis
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Allen Dennis were reported at $9,564. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Allen Dennis Interventional Pain Medicine median Middle half National median
2019 $2,745 $684 $216–$2,079 $163
2020 $2,831 $382 $122–$1,109 $114
2021 $5,950 $552 $167–$1,554 $132
2022 $14,851 $605 $187–$1,924 $149
2023 $4,182 $671 $195–$1,915 $160
2024 $11,515 $684 $206–$1,837 $164
2025 $9,564 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $47,963 1,042 payments
  2. Boston Scientific Corporation $1,642 117 payments
  3. AbbVie, Inc. $445 31 payments
  4. Spinal Simplicity, LLC $129 1 payment
  5. Nalu Medical, Inc. $122 1 payment
  6. Pfizer Inc. $106 7 payments
  7. Curonix LLC $98 1 payment
  8. Collegium Pharmaceutical, Inc. $94 5 payments
  9. Janssen Biotech, Inc. $91 4 payments
  10. Foundation Fusion Solutions, LLC $88 2 payments
  11. Other $861 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $21,992 1,221 payments
  2. Consulting Fee $20,488 17 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $5,500 7 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,538 9 payments
  5. Entertainment $66 1 payment
  6. Education $56 5 payments
Products named General payments · program years 2019–2025
  1. PROCLAIM Neuromodulation $23,050 126 payments
  2. PROCLAIM Structural Heart $8,892 12 payments
  3. OCTRODE Neuromodulation $4,832 153 payments
  4. Proclaim IPG $3,510 190 payments
  5. Proclaim Family of SCS IPGs $2,212 163 payments
  6. GENERAL PAIN MANAGEMENT $1,158 89 payments
  7. Octrode SCS Leads Neuromodulation $1,127 103 payments
  8. Octrode SCS Leads Cardiac Arrhythmias and Heart Failure $697 69 payments
  9. PROCLAIM Neuromodulation $458 6 payments
  10. OCTRODE Structural Heart $420 5 payments
  11. Other $5,539 366 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

5,700

Median for Interventional Pain Management: 1,220

Drug cost

$218,734

Median for Interventional Pain Management: $39,344

Branded share of claims

64.4%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 2,397 $63,252
Xtampza Er Oxycodone Myristate Brand 94 $43,647
Oxycontin Oxycodone Hcl Brand 76 $34,278
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 644 $18,975
Morphine Sulfate Er Morphine Sulfate Brand 422 $18,788
Oxycodone Hcl Generic 807 $12,316
Fentanyl Generic 95 $11,227
Hydromorphone Hcl Generic 262 $3,186
Gabapentin Generic 140 $1,490
Pregabalin Generic 64 $1,313

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 106 billing codes

Paid by Medicare

$308,882

Of which drugs: $2,262

Medicare patients

634

Average age 73

Services billed

3,804

428 women, 206 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Depression 37%
Diabetes 32%
Ischemic heart disease 30%
Heart failure 23%
Osteoporosis 23%
Chronic kidney disease 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 25 150 $107
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 14 154 $14

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
$31 — —
GIVLAARI
$26 — —
TREMFYA
$23 — —
NURTEC ODT
$20 — —
ZAVZPRET
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

1,260 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record